Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PP-001
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Jiangsu Simcere Pharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Simcere Pharmaceutical Group and Primary Peptides Inc. Announce Exclusive China Partnership
Details : Simcere receives exclusive rights to develop and commercialize in China, including the mainland, Hong Kong, Macau and Taiwan while Primary Peptides retains rights in all other markets.
Product Name : PP-001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 05, 2020
Lead Product(s) : PP-001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Jiangsu Simcere Pharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : PP-002
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Qingdao Primedicine Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the Partnership, Primedicine receives exclusive rights to develop and commercialize in China, including the mainland, Hong Kong, Macau and Taiwan while Primary Peptides retains rights in all other markets. Financial terms were not disc...
Product Name : PP-002
Product Type : Peptide
Upfront Cash : Undisclosed
May 19, 2020
Lead Product(s) : PP-002
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Qingdao Primedicine Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement